Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 4/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GALK1 | P51570 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669039 | 1.00 | HSD11B1 (0.48) | HSD11B1NPY5RNOTUMOPRM1SIGMAR1 | |
| SCHEMBL3031539 | 0.86 | MAPT (0.51) | HSD11B1NPY5ROPRM1SIGMAR1TRPV4 | |
| SCHEMBL3031925 | 0.86 | NPY5R (0.48) | HSD11B1NPY5RNOTUMOPRM1SIGMAR1 | |
| SCHEMBL3031924 | 0.86 | NPY5R (0.48) | HSD11B1NPY5RNOTUMOPRM1SIGMAR1 | |
| SCHEMBL3670723 | 0.86 | MAPT (0.51) | HSD11B1NPY5ROPRM1SIGMAR1TRPV4 | |
| SCHEMBL2995097 | 0.84 | OPRM1 (0.53) | HSD11B1NPY5RNOTUMOPRM1SIGMAR1 | |
| SCHEMBL2999026 | 0.84 | OPRM1 (0.53) | HSD11B1NPY5RNOTUMOPRM1SIGMAR1 | |
| SCHEMBL3000010 | 0.84 | OPRM1 (0.53) | HSD11B1NPY5RNOTUMOPRM1SIGMAR1 | |
| SCHEMBL3036715 | 0.83 | HSD11B1 (0.48) | HSD11B1NPY5ROPRM1SIGMAR1KCNH2 | |
| SCHEMBL3041083 | 0.80 | NPY5R (0.54) | HSD11B1NPY5RKCNH2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| EP-2139861-A1 | BENZIMIDAZOLES WITH A HETERO SPIRO-DECANE RESIDUE AS NPY-Y5 ANTAGONISTS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008129007-A1 | BENZIMIDAZOLES WITH A HETERO SPIRO-DECANE RESIDUE AS NPY-Y5 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008129007-A1 | BENZIMIDAZOLES WITH A HETERO SPIRO-DECANE RESIDUE AS NPY-Y5 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | NPY5R, NPY4R, NPY1R | HSD11B1 1359/4885NPY5R 1/4885NOTUM 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.